Asthma Treatment Market
Asthma Treatment Market Study by Inhaled, Oral, Intravenous, and Subcutaneous for Long-term Asthma Control Medications and and Quick-relief (Rescue) Medications from 2023 to 2033
Analysis of Asthma Treatment Market Covering 30+ Countries Including Analysis of US, Canada, UK, Germany, France, Nordics, GCC countries, Japan, Korea and many more
Asthma Treatment Market Outlook (2023 to 2033)
Global demand for asthma treatment is forecasted to register an increase at 3.2% CAGR from 2023 and 2033, currently accounting for a market value of US$ 25.8 billion. By the end of 2033, the global asthma treatment market is projected to reach a revenue of US$ 35.4 billion.
In recent years, the prevalence of chronic disorders has increased noticeably and this trend has resulted in high demand for novel treatments and therapies to treat these chronic disorders, which is a prime factor that is expected to boost asthma treatment demand in the future. Increasing air pollution, poor lifestyle choices resulting in a weak immune system, high incidence of psychological disorders, high incidence of asthma in young people, and rising investments in research and development of new asthma medicines are other aspects that could bolster demand for asthma care through 2033.
Rising investments in medical research and supportive initiatives by the government to bolster healthcare infrastructure development are also anticipated to have a positive impact on the sales of medicine for asthma cough and other asthma symptoms.
- In June 2022, The National Institutes of Health announced the launch of a new trial to explore monoclonal antibody treatment of asthma in young people. The clinical trial was launched to explore the use of dupilumab to improve lung function and reduce the frequency of asthma attacks among children living in low-income urban neighborhoods.
The high ubiquity of respiratory disorders and asthma has resulted in increased demand for breathing difficulty treatments and this is why many pharmaceutical and biotechnology companies have invested in the development and launch of new asthma therapeutics. These companies are now getting approvals from regulatory authorities to commercialize novel treatments and asthma medicine to help people around the world.
- In March 2022, the United States Food and Drug Administration (FDA) announced the approval of a generic drug-device combination product for the treatment of asthma in patients six years of age or older and chronic obstructive pulmonary disease (COPD) as well.
On the flip side, lack of adherence to asthma treatment and high costs of asthma care products and medications are anticipated to have a restraining effect on the market growth across the forecast period. The use of biologics to treat asthma is a trend that is anticipated to open up new avenues of opportunities for incoming asthma treatment companies as well as established market players going forward.
This latest asthma treatment market research survey by Fact.MR, a market research and competitive intelligence provider, details a comprehensive account of trends such as global demand, product standards, new developments, local supply, etc., to provide a realistic current and forecasted assessment of the marketplace.
| Report Attributes | Details |
|---|---|
| Asthma Treatment Market Size (2023) | US$ 25.8 Billion |
| Projected Market Value (2033F) | US$ 35.4 Billion |
| Global Market Growth Rate (2023 to 2033) | 3.2% CAGR |
| North America Market Share (2022) | ~40% |
| Long-term Asthma Control Medications Segment Market Share (2022) | >50% |
| Online Pharmacies Segment Market Growth Rate (2023 to 2033) | 3.7% CAGR |
| Key Companies Profiled | Boehringer Ingelheim International GmbH; Teva Pharmaceutical Industries Ltd.; AstraZeneca; Merck & Co. Inc.; Novartis AG; Sanofi; F. Hoffmann-La Roche Ltd.; Sumitomo Dainippon Pharma Co. Ltd.; Mylan N.V.; GlaxoSmithKline Plc |
How Can Start-ups Transform the Asthma Care Industry?
“New Companies Focusing on Asthma Management to Revolutionize Asthma Care”
New asthma treatment companies are focusing on developing new and innovative asthma management solutions to help patients take better care of themselves. These new solutions are also helping healthcare professionals in obtaining better information on a patient’s condition and health.
- Redecol Ltd., a start-up founded in 2017 and located in the United Kingdom is creating novel sensor technology that helps in asthma management and monitoring. The breath sensors developed by this company analyze the breath profile to identify potential asthma attacks and also provides insights into lung performance. The sensor also tracks the incidence of these asthma attacks to enable proactive patient care.
- Strados Labs, a United States-based start-up develops an RESP (Remote E- Stethoscope Platform) that helps medical professionals in the treatment of respiratory disorders. The E-stethoscope is a wearable device that is capable of recording crucial data and then uploading it to the cloud for doctors to access.
More new developments by start-ups and their impact on supply chain management have been detailed in this recently updated Fact.MR research analysis.
Country-wise Insights
Which Factors are Crucially Shaping Asthma Care Demand in Asian Countries?
“Growing Air Pollution and Rising Availability of Asthma Medications”
Rapid urbanization and industrialization in the Asia Pacific region have resulted in increased air pollution in most Asian countries and this is expected to be a prime factor contributing to the high prevalence of asthma among Asian people. India, China, Japan, and Korea are projected to be the key markets for asthma care providers in the future owing to rising awareness regarding the symptoms of asthma and other chronic obstructive pulmonary diseases (COPDs).
Generic asthma drugs, over-the-counter asthma medications, and asthma breathing machines are expected to be some popular products that could witness a hike in demand throughout the forecast period. Homeopathy medicine for asthma and herbs for asthma treatment are also anticipated to be in demand in the aforementioned Asian countries owing to rising awareness regarding the benefits of traditional medicine.
How Will Demand for Asthma Treatment Fare in Europe?
“Adoption of Novel Asthma Treatment & Therapeutics in the Region”
Europe is projected to emerge as the second-most lucrative regional market for asthma treatment across the forecast period owing to the rising incidence of asthma among children in several European countries. High investments in infrastructure development are boosting the adoption of new asthma therapeutics and novel treatments for asthmatics in countries such as the United Kingdom, Germany, and France.
It is estimated that nearly 30 million people are affected by asthma in the European region. The rising prevalence of psychological disorders, growing air pollution, and increasing pet ownership are other factors that are projected to propel the demand for OTC asthma medications, nebulizer medicines, cough medicines, medication for wheezing, asthma spacers, etc. over the next ten years in European countries.
Why are Asthma Treatment Providers Eyeing the United States?
“High Prevalence of Asthma Driving Demand for Asthma Care”
The United States is the most lucrative market for asthma treatment providers in the North American region owing to the high incidence of asthma and growing awareness regarding novel asthma therapeutics. High investments in asthma research, the launch of novel asthma treatment products by established companies, favorable reimbursement policies, and high healthcare expenditure are other aspects that could bolster demand for asthma treatment in the country across the forecast period.
- As per the statistics provided by the Asthma and Allergy Foundation of America, nearly 25 million people in the United States suffer from asthma, which equated to around 1 in 13 people. Black adults in the country account for the highest rate of asthma.
Increasing support from the government to develop novel treatments for asthma and the rising frequency of approval for new asthma therapeutics by the Food and Drug Administration of the United States (FDA) are other factors that are estimated to create new opportunities for established as well as upcoming asthma treatment providers in the country.
Category-wise Insights
Which Treatment is Generally Preferred for Treating Asthma?
“Long-term Asthma Control Medications to Account for Significant Market Share”
Based on treatment, the market for asthma treatments is segmented into long-term asthma control medications and quick-relief (rescue) medications.
Most chronic ailments are often treated with long-term medications and this is true in the case of asthma as well, which is projected to result in high demand for long-term asthma control medications across the forecast period. Asthma exacerbations are prevented by using controlled medications over a long period that help in the reduction of inflammation.
Long-acting inhalers are projected to be the most popular long-term asthma control medications over the next ten years owing to rising awareness regarding their efficacy in the treatment of the condition. Long-term asthma control medications accounted for more than 50% share of the global market in 2022.
Quick-relief medications or rescue medications are used for the treatment of short breaths, wheezing, coughing, etc., which are acute symptoms of asthma that require immediate care. The quick-relief (rescue) medications segment is further bifurcated into short-acting beta-agonists, Ipratropium (Atrovent), and oral & intravenous corticosteroids.
Competitive Landscape
Prime asthma treatment companies are focusing on launching new treatment drugs to maximize their sales potential and gain a competitive advantage over other market players in the industry landscape.
- In January 2023, Lupin, a multinational pharmaceutical company based in India announced the launch of a new drug combination to manage and treat asthma among patients. The new fixed-dose triple drug combination (FDC) of Indacaterol, Glycopyrronium, and Mometasone was launched under the brand name DIFIZMA in India.
Key Segments of Asthma Treatment Industry Research
-
By Treatment :
- Long-term Asthma Control Medications
- Combination Inhalers
- Inhaled Corticosteroids
- Long-acting Beta Agonists
- Leukotriene Modifiers
- Theophylline
- Others (Reslizumab, Benralizumab, etc.)
- Quick-relief (Rescue) Medications
- Short-acting Beta Agonists
- Ipratropium (Atrovent)
- Oral & Intravenous Corticosteroids
- Long-term Asthma Control Medications
-
By Route of Administration :
- Inhaled
- Oral
- Intravenous
- Subcutaneous
-
By Distribution Channel :
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
-
By Region :
- North America
- Latin America
- Europe
- APAC
- MEA
Table of Content
- 1. Preface
- 2. Assumptions and Research Methodology
- 3. Executive Summary: Global Market
- 4. Market Overview
- 5. Market Outlook
- 6. Global Market Analysis and Forecasts, by Treatment Type
- 6.1. Long-term Asthma Control Medications
- 6.1.1. Inhaled Corticosteroids
- 6.1.2. Leukotriene Modifiers
- 6.1.3. Long-acting Beta Agonists
- 6.1.4. Combination Inhalers
- 6.1.5. Theophylline
- 6.1.6. Others (reslizumab, benralizumab, etc.)
- 6.2. Quick-relief (rescue) Medications
- 6.2.1. Short-acting Beta Agonists
- 6.2.2. Ipratropium (Atrovent)
- 6.2.3. Oral and Intravenous Corticosteroids
- 6.1. Long-term Asthma Control Medications
- 7. Global Market Analysis and Forecasts, by Route of Administration
- 7.1. Oral
- 7.2. Inhaled
- 7.3. Intravenous
- 7.4. Subcutaneous
- 8. Global Market Analysis and Forecasts, by Distribution Channel
- 8.1. Hospital Pharmacies
- 8.2. Retail Pharmacies
- 8.3. Online Pharmacies
- 9. Global Market Analysis and Forecasts, by Region
- 9.1. North America
- 9.2. Europe
- 9.3. Asia Pacific
- 9.4. Latin America
- 9.5. Middle East & Africa
- 10. North America Market Analysis and Forecast
- 11. Europe Market Analysis and Forecast
- 12. Asia Pacific Market Analysis and Forecast
- 13. Latin America Market Analysis and Forecast
- 14. Middle East & Africa Market Analysis and Forecast
- 15. Competition Landscape
- 15.1. AstraZeneca
- 15.2. Boehringer Ingelheim International GmbH
- 15.3. GlaxoSmithKline plc
- 15.4. Novartis AG
- 15.5. Teva Pharmaceutical Industries Ltd
- 15.6. Sumitomo Dainippon Pharma Co., Ltd
- 15.7. Merck & Co., Inc.
- 15.8. F. Hoffmann-La Roche Ltd.
- 15.9. Sanofi
- 15.10. Mylan N.V.
List Of Table
Table 01: Pipeline Analysis
Table 02: Pipeline Analysis
Table 03: Pipeline Analysis
Table 04: Global Market Value (US$ Mn) Forecast, by Treatment Type, 2023 to 2033
Table 05: Global Market Value (US$ Mn) Forecast, by Long-term Asthma Control Medications, 2023 to 2033
Table 06: Global Market Value (US$ Mn) Forecast, by Quick-relief (rescue) Medications, 2023 to 2033
Table 07: Global Market Value (US$ Mn) Forecast, by Route of Administration, 2023 to 2033
Table 08: Global Market Value (US$ Mn) Forecast, by Distribution Channel, 2023 to 2033
Table 09: Global Market Value (US$ Mn) Forecast, by Region, 2023 to 2033
Table 10: North America Market Value (US$ Mn) Forecast, by Treatment Type, 2023 to 2033
Table 11: North America Market Value (US$ Mn) Forecast, by Long-term Asthma Control Medications, 2023 to 2033
Table 12: North America Market Value (US$ Mn) Forecast, by Quick-relief (rescue) Medications, 2023 to 2033
Table 13: North America Market Value (US$ Mn) Forecast, by Route of Administration, 2023 to 2033
Table 14: North America Market Value (US$ Mn) Forecast, by Distribution Channel, 2023 to 2033
Table 15: North America Market Value (US$ Mn) Forecast, by Country/Sub-region, 2023 to 2033
Table 16: Europe Market Value (US$ Mn) Forecast, by Treatment Type, 2023 to 2033
Table 17: Europe Market Value (US$ Mn) Forecast, by Long-term Asthma Control Medications, 2023 to 2033
Table 18: Europe Market Value (US$ Mn) Forecast, by Quick-relief (rescue) Medications, 2023 to 2033
Table 19: Europe Market Value (US$ Mn) Forecast, by Route of Administration, 2023 to 2033
Table 20: Europe Market Value (US$ Mn) Forecast, by Distribution Channel, 2023 to 2033
Table 21: Europe Market Value (US$ Mn) Forecast, by Country/Sub-region, 2023 to 2033
Table 22: Asia Pacific Market Value (US$ Mn) Forecast, by Treatment Type, 2023 to 2033
Table 23: Asia Pacific Market Value (US$ Mn) Forecast, by Long-term Asthma Control Medications, 2023 to 2033
Table 24: Asia Pacific Market Value (US$ Mn) Forecast, by Quick-relief (rescue) Medications, 2023 to 2033
Table 25: Asia Pacific Market Value (US$ Mn) Forecast, by Route of Administration, 2023 to 2033
Table 26: Asia Pacific Market Value (US$ Mn) Forecast, by Distribution Channel, 2023 to 2033
Table 27: Asia Pacific Market Value (US$ Mn) Forecast, by Country/Sub-region, 2023 to 2033
Table 28: Latin America Market Value (US$ Mn) Forecast, by Treatment Type, 2023 to 2033
Table 29: Latin America Market Value (US$ Mn) Forecast, by Long-term Asthma Control Medications, 2023 to 2033
Table 30: Latin America Market Value (US$ Mn) Forecast, by Quick-relief (rescue) Medications, 2023 to 2033
Table 31: Latin America Market Value (US$ Mn) Forecast, by Route of Administration, 2023 to 2033
Table 32: Latin America Market Value (US$ Mn) Forecast, by Distribution Channel, 2023 to 2033
Table 33: Latin America Market Value (US$ Mn) Forecast, by Country/Sub-region, 2023 to 2033
Table 34: Middle East & Africa Market Value (US$ Mn) Forecast, by Treatment Type, 2023 to 2033
Table 35: Middle East & Africa Market Value (US$ Mn) Forecast, by Long-term Asthma Control Medications, 2023 to 2033
Table 36: Middle East & Africa Market Value (US$ Mn) Forecast, by Quick-relief (rescue) Medications, 2023 to 2033
Table 37: Middle East & Africa Market Value (US$ Mn) Forecast, by Route of Administration, 2023 to 2033
Table 38: Middle East & Africa Market Value (US$ Mn) Forecast, by Distribution Channel, 2023 to 2033
Table 39: Middle East & Africa Market Value (US$ Mn) Forecast, by Country/Sub-region, 2023 to 2033
List Of Figures
Figure 01: Global Market Value (US$ Mn) and Distribution Channel, by Region, 2022 and 2033
Figure 02: Global Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2023 to 2033
Figure 03: Global Market Value Share Analysis, by Treatment Type, 2022 and 2033
Figure 04: Global Market Value (US$ Mn) and Y-o-Y Growth (%), by Long-term Asthma Control Medications, 2023 to 2033
Figure 05: Global Market Value (US$ Mn) and Y-o-Y Growth (%), by Quick-relief (rescue) Medications, 2023 to 2033
Figure 06: Global Market Attractiveness Analysis, by Treatment Type, 2022 to 2033
Figure 07: Global Market Value Share Analysis, by Route of Administration, 2022 and 2033
Figure 08: Global Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Inhaled, 2023 to 2033
Figure 09: Global Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Oral, 2023 to 2033
Figure 10: Global Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Intravenous, 2023 to 2033
Figure 11: Global Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Subcutaneous, 2023 to 2033
Figure 12: Global Market Attractiveness Analysis, by Route of Administration, 2022 to 2033
Figure 13: Global Market Value Share Analysis, by Distribution Channel, 2022 and 2033
Figure 14: Global Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Retail Pharmacies, 2023 to 2033
Figure 15: Global Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Hospital Pharmacies, 2023 to 2033
Figure 16: Global Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Online Pharmacies, 2023 to 2033
Figure 17: Global Market Attractiveness Analysis, by Distribution Channel, 2022 to 2033
Figure 18: Global Market Value Share Analysis, by Region, 2022 and 2033
Figure 19: Global Market Attractiveness Analysis, by Region, 2022 to 2033
Figure 20: North America Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2023 to 2033
Figure 21: North America Market Value Share Analysis, by Treatment Type, 2022 and 2033
Figure 22: North America Market Attractiveness Analysis, by Treatment Type, 2022 to 2033
Figure 23: North America Market Value Share Analysis, by Route of Administration, 2022 and 2033
Figure 24: North America Market Attractiveness Analysis, by Route of Administration, 2022 to 2033
Figure 25: North America Market Value Share Analysis, by Distribution Channel, 2022 and 2033
Figure 26: North America Market Attractiveness Analysis, by Distribution Channel, 2022 to 2033
Figure 27: North America Market Value Share Analysis, by Country, 2022 and 2033
Figure 28: North America Market Attractiveness Analysis, by Country, 2022 to 2033
Figure 29: Europe Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2023 to 2033
Figure 30: Europe Market Value Share Analysis, by Treatment Type, 2022 and 2033
Figure 31: Europe Market Attractiveness Analysis, by Treatment Type, 2022 to 2033
Figure 32: Europe Market Value Share Analysis, by Route of Administration, 2022 and 2033
Figure 33: Europe Market Attractiveness Analysis, by Route of Administration, 2022 to 2033
Figure 34: Europe Market Value Share Analysis, by Distribution Channel, 2022 and 2033
Figure 35: Europe Market Attractiveness Analysis, by Distribution Channel, 2022 to 2033
Figure 36: Europe Market Value Share Analysis, by Country/Sub-Region, 2022 and 2033
Figure 37: Europe Market Attractiveness Analysis, by Country/Sub-region, 2022 to 2033
Figure 38: Asia Pacific Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2023 to 2033
Figure 39: Asia Pacific Market Value Share Analysis, by Treatment Type, 2022 and 2033
Figure 40: Asia Pacific Market Attractiveness Analysis, by Treatment Type, 2023 to 2033
Figure 41: Asia Pacific Market Value Share Analysis, by Route of Administration, 2022 and 2033
Figure 42: Asia Pacific Market Attractiveness Analysis, by Route of Administration, 2022 to 2033
Figure 43: Asia Pacific Market Value Share Analysis, by Distribution Channel, 2022 and 2033
Figure 44: Asia Pacific Market Attractiveness Analysis, by Distribution Channel, 2022 - 2033
Figure 45: Asia Pacific Market Value Share Analysis, by Country/Sub-region, 2022 and 2033
Figure 46: Asia Pacific Market Attractiveness Analysis, by Country/Sub-region, 2022 to 2033
Figure 47: Latin America Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2023 to 2033
Figure 48: Latin America Market Value Share Analysis, by Treatment Type, 2022 and 2033
Figure 49: Latin America Market Attractiveness Analysis, by Treatment Type, 2022 to 2033
Figure 50: Latin America Market Value Share Analysis, by Route of Administration, 2022 and 2033
Figure 51: North America Market Attractiveness Analysis, by Route of Administration, 2022 to 2033
Figure 52: Latin America Market Value Share Analysis, by Distribution Channel, 2022 and 2033
Figure 53: Latin America Market Attractiveness Analysis, by Distribution Channel, 2022 to 2033
Figure 54: Latin America Market Value Share Analysis, by Country/Sub-region, 2022 and 2033
Figure 55: Latin America Market Attractiveness Analysis, by Country/Sub-region, 2022 to 2033
Figure 56: Middle East & Africa Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2023 to 2033
Figure 57: Middle East & Africa Market Value Share Analysis, by Treatment Type, 2022 and 2033
Figure 58: Middle East & Africa Market Attractiveness Analysis, by Treatment Type, 2022 to 2033
Figure 59: Middle East & Africa Market Value Share Analysis, by Route of Administration, 2022 and 2033
Figure 60: Middle East & Africa Market Attractiveness Analysis, by Route of Administration, 2022 to 2033
Figure 61: Middle East & Africa Market Value Share Analysis, by Distribution Channel, 2022 and 2033
Figure 62: Middle East & Africa Market Attractiveness Analysis, by Distribution Channel, 2022?2033
Figure 63: Middle East & Africa Market Value Share Analysis, by Country/Sub-region, 2022 and 2033
Figure 64: Middle East & Africa Market Attractiveness Analysis, by Country/Sub-region, 2022 to 2033
Figure 65: Global Market Share, by Company, 2022
Figure 66: AstraZeneca Revenue (US$ Mn) and Y-o-Y Growth (%), 2018 to 2022
Figure 67: AstraZeneca Respiratory Segment Revenue (US$ Mn) and Y-o-Y Growth (%), 2018 to 2022
Figure 68: AstraZeneca Breakdown of Net Sales (%), by Product Segment, 2022
Figure 69: Boehringer Ingelheim International GmbH Revenue (US$ Mn) and Y-o-Y Growth (%), 2018 to 2022
Figure 70: Boehringer Ingelheim International GmbH Breakdown of Net Sales (%), by Region, 2022
Figure 71: Boehringer Ingelheim International GmbH R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2018 to 2022
Figure 72: Boehringer Ingelheim International GmbH Breakdown of Net Sales (%), by Business Segment, 2022
Figure 73: GlaxoSmithKline plc Revenue (US$ Mn) and Y-o-Y Growth (%), 2018 to 2022
Figure 74: GlaxoSmithKline plc Breakdown of Net Sales (%), by Region, 2022
Figure 75: GlaxoSmithKline plc R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2018 to 2022
Figure 76: GlaxoSmithKline plc Breakdown of Net Sales (%), by Business Segment, 2022
Figure 77: Novartis AG Revenue (US$ Mn) and Y-o-Y Growth (%), 2018 to 2022
Figure 78: Novartis AG Breakdown of Net Sales (%), by Country, 2022
Figure 79: Novartis AG R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2018 to 2022
Figure 80: Novartis AG Breakdown of Net Sales (%), by Business Segment, 2022
Figure 81: Teva Pharmaceutical Industries Ltd Revenue (US$ Mn) and Y-o-Y Growth (%), 2018 to 2022
Figure 82: Teva Pharmaceutical Industries Ltd R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2018 to 2022
Figure 83: Teva Pharmaceutical Industries Ltd Breakdown of Net Sales (%), by Segment, 2022
Figure 84: Sumitomo Dainippon Pharma Co., Ltd Revenue (US$ Mn) and Y-o-Y Growth (%), 2014 to 2022
Figure 85: Sumitomo Dainippon Pharma Co., Ltd Breakdown of Pharmaceutical Net Sales (%), by Region, 2017
Figure 86: Sumitomo Dainippon Pharma Co., Ltd R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2014 to 2022
Figure 87: Breakdown of Sumitomo Dainippon Pharma Co., Ltd Net Sales (%), by Product Segment, 2017
Figure 88: Merck & Co., Inc. Revenue (US$ Mn) and Y-o-Y Growth (%), 2018 to 2022
Figure 89: Merck & Co., Inc. Breakdown of Net Sales (%), by Region, 2022
Figure 90: Merck & Co., Inc. R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2018 to 2022
Figure 91: Merck & Co., Inc. Breakdown of Net Sales (%), by Business Segment, 2022
Figure 92: F. Hoffmann-La Roche Ltd. Revenue (US$ Mn) and Y-o-Y Growth (%), 2018 to 2022
Figure 93: F. Hoffmann-La Roche Ltd. Breakdown of Net Sales (%), by Region, 2022
Figure 94: F. Hoffmann-La Roche Ltd. R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2018 to 2022
Figure 95: F. Hoffmann-La Roche Ltd. Breakdown of Net Sales (%), by Business Segment, 2022
Figure 96: Sanofi Revenue (US$ Mn) and Y-o-Y Growth (%), 2018 to 2022
Figure 97: Sanofi Breakdown of Net Sales (%), by Region, 2022
Figure 98: Sanofi Revenue Breakdown of Net Sales (%), by Business segment, 2022
Figure 99: Sanofi R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2018 to 2022
Figure 100: Mylan N.V. Revenue (US$ Mn) and Y-o-Y Growth (%), 2018 to 2022
Figure 101: Mylan N.V. R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2018 to 2022
Figure 102: Mylan N.V. Breakdown of Net Sales (%), by Region, 2022
- FAQs -
How big is the asthma treatment market?
The global asthma treatment market accounts for a value of US$ 25.8 billion in 2023.
What is the projected market size for asthma treatment?
The market for asthma treatment is extrapolated to reach US$ 35.4 billion by 2033-end.
At what pace will the market evolve?
Worldwide asthma treatment demand is set to rise at 3.2% CAGR from 2023 to 2033.
Which regional market accounts for a leading market share?
North America held a significant share of more than 40% of the global market in 2022.
Who are the key asthma treatment providers?
AstraZeneca, Merck & Co. Inc., Novartis AG, Sanofi, and Mylan N.V. are some of the prime companies operating in this market.
Asthma Treatment Market